1 |
Linnemann B. Antiphospholipid syndrome-an update [J]. Vasa, 2018, 47(6): 451-464.
|
2 |
Baker PJ. Is it possible to make a correct diagnosis of Lyme disease on symptoms alone? Review of key issues and public health implications [J]. Am J Med, 2019, 132(10): 1148-1152.
|
3 |
Garcia Monco JC, Wheeler CM, Benach JL, et al. Reactivity of neuroborreliosis patients (Lyme disease) to cardiolipin and gangliosides [J]. J Neurol Sci, 1993, 117(1-2): 206-214.
|
4 |
Zabek J, Chodynicka B, Luft S, et al. Differences of the specificity and of beta2-glycoprotein I necessity as cofactor of antiphospholipid antibodies in infectious and autoimmune diseases [J]. Reumatologia (Warsaw), 2001, 39(2): 115-124.
|
5 |
Greco TP, Jr., Conti-Kelly AM, Greco TP. Antiphospholipid antibodies in patients with purported 'chronic Lyme disease' [J]. Lupus, 2011, 20(13): 1372-1377.
|
6 |
Lis-Swiety A, Brzezniska-Wcislo L, Arasiewicz H, et al. Antiphospholipid antibodies in localized scleroderma: the potential role of screening tests for the detection of antiphospholipid syndrome [J]. Postepy Dermatol Alergol, 2014, 31(2): 65-70.
|
7 |
Bertolaccini ML, Amengual O, Andreoli L, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends [J]. Autoimmun Rev, 2014, 13(9): 917-930.
|
8 |
Hunt JE, Mcneil HP, Morgan GJ, et al. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection [J]. Lupus, 1992, 1(2): 75-81.
|
9 |
Asherson RA, Cervera R. Antiphospholipid antibodies and infections [J]. Ann Rheum Dis, 2003, 62(5): 388-393.
|
10 |
Hojnik M, Gilburd B, Ziporen L, et al. Anticardiolipin antibodies in infections are heterogenous in their dependency on beta 2-glycoprotein I: analysis of anticardiolipin antibodies in leprosy [J]. Lupus, 1994, 3(6): 515-521.
|
11 |
Pengo V, Bison E, Denas G, et al. Laboratory Diagnostics of Antiphospholipid Syndrome [J]. Semin Thromb Hemost, 2018, 44(5): 439-444.
|